Abstract

FRAGOZO-RAMOS, Maria C. et al. Inclisiran, small interfering RNA: a new approach to cholesterol treatment. Rev. Colomb. Cardiol. [online]. 2022, vol.29, n.6, pp.663-675.  Epub Dec 27, 2022. ISSN 0120-5633.  https://doi.org/10.24875/rccar.21000150.

Hyperlipidemia is a highly prevalent condition and contributes substantially to atherosclerotic cardiovascular disease (ASCVD), which is one of the main causes of morbidity and mortality in Colombia. The reduction of LDL cholesterol (LDL-C) decreases the risk of ASCVD and adverse cardiovascular events. Targeted therapy for the proprotein convertase subtilisin/kexin type 9 (PCSK-9) has emerged as a novel tool for the treatment of hyperlipidemia. Inclisiran is a small double-stranded small interfering RNA that acts by blocking PCSK-9 transcription in hepatocytes, leading to a marked and sustained reduction in circulating LDL-C levels. In contrast to other lipid-lowering therapies such as statins, ezetimibe and monoclonal antibodies (MAbs) PCSK-9 inhibitors, Inclisiran proposes an infrequent dosing regimen of twice or three times a year. Its prolonged effect represents an advantage over non-compliance of the treatment, which is one of the main reasons why LDL-C goals are not achieved with standard therapy. This review aims to present and discuss current scientific data regarding the efficacy, tolerability and safety of Inclisiran in the treatment of hypercholesterolemia.

Keywords : Hypercholesterolemia; Proprotein convertase subtilisin/kexin 9; Inclisiran; ALN PCS; Atherosclerotic cardiovascular disease.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )